Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide

Background: The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease. Thalidomide has been described as inhibitor of the fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF). Therefore and in considerat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraemer, Anja, Hauser, Stefan, Kim, Young, Gorschlüter, Marcus, Müller, Stefan C., Brossart, Peter, Schmidt-Wolf, Ingo G. H.
Formato: Texto
Lenguaje:English
Publicado: German Medical Science GMS Publishing House 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716555/
https://www.ncbi.nlm.nih.gov/pubmed/19675744
http://dx.doi.org/10.3205/000063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716555/
https://www.ncbi.nlm.nih.gov/pubmed/19675744
http://dx.doi.org/10.3205/000063

Ejemplares similares